Roche announced a series of new intended uses for two key cardiac biomarkers using the Elecsys technology: high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide (NT-proBNP).
One of the new intended uses for Elecsys NT-proBNP helps healthcare professionals identify which people with type-2 diabetes are at higher risk of developing cardiovascular disease. The second newly launched intended use for NT-proBNP provides healthcare professionals with a biomarker-based solution that identifies people at risk of developing atrial fibrillation (AF), an abnormal heart rhythm that can lead to stroke, brain damage and death.
Another biomarker, Elecsys cTnT-hs, now provides healthcare professionals with data to help predict heart attack risk and mortality in non-cardiac surgery patients.
